These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 12626750)

  • 1. Potent inhibition of scrapie prion replication in cultured cells by bis-acridines.
    May BC; Fafarman AT; Hong SB; Rogers M; Deady LW; Prusiner SB; Cohen FE
    Proc Natl Acad Sci U S A; 2003 Mar; 100(6):3416-21. PubMed ID: 12626750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Acridine and phenothiazine derivatives as pharmacotherapeutics for prion disease.
    Korth C; May BC; Cohen FE; Prusiner SB
    Proc Natl Acad Sci U S A; 2001 Aug; 98(17):9836-41. PubMed ID: 11504948
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiprion activity of functionalized 9-aminoacridines related to quinacrine.
    Nguyen TH; Lee CY; Teruya K; Ong WY; Doh-ura K; Go ML
    Bioorg Med Chem; 2008 Jul; 16(14):6737-46. PubMed ID: 18556207
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis of monomeric and dimeric acridine compounds as potential therapeutics in Alzheimer and prion diseases.
    Csuk R; Barthel A; Raschke C; Kluge R; Ströhl D; Trieschmann L; Böhm G
    Arch Pharm (Weinheim); 2009 Dec; 342(12):699-709. PubMed ID: 19899100
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemical chaperones interfere with the formation of scrapie prion protein.
    Tatzelt J; Prusiner SB; Welch WJ
    EMBO J; 1996 Dec; 15(23):6363-73. PubMed ID: 8978663
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemically induced accumulation of GAGs delays PrP(Sc) clearance but prolongs prion disease incubation time.
    Mayer-Sonnenfeld T; Avrahami D; Friedman-Levi Y; Gabizon R
    Cell Mol Neurobiol; 2008 Nov; 28(7):1005-15. PubMed ID: 18350378
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Copaxone interferes with the PrP Sc-GAG interaction.
    Engelstein R; Ovadia H; Gabizon R
    Eur J Neurol; 2007 Aug; 14(8):877-84. PubMed ID: 17662008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cyclodextrins inhibit replication of scrapie prion protein in cell culture.
    Prior M; Lehmann S; Sy MS; Molloy B; McMahon HE
    J Virol; 2007 Oct; 81(20):11195-207. PubMed ID: 17699584
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A chimeric ligand approach leading to potent antiprion active acridine derivatives: design, synthesis, and biological investigations.
    Dollinger S; Löber S; Klingenstein R; Korth C; Gmeiner P
    J Med Chem; 2006 Nov; 49(22):6591-5. PubMed ID: 17064077
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthesis and SAR study of acridine, 2-methylquinoline and 2-phenylquinazoline analogues as anti-prion agents.
    Cope H; Mutter R; Heal W; Pascoe C; Brown P; Pratt S; Chen B
    Eur J Med Chem; 2006 Oct; 41(10):1124-43. PubMed ID: 16782236
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-activity relationship study of 9-aminoacridine compounds in scrapie-infected neuroblastoma cells.
    May BC; Witkop J; Sherrill J; Anderson MO; Madrid PB; Zorn JA; Prusiner SB; Cohen FE; Guy RK
    Bioorg Med Chem Lett; 2006 Sep; 16(18):4913-6. PubMed ID: 16860557
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiprion properties of prion protein-derived cell-penetrating peptides.
    Löfgren K; Wahlström A; Lundberg P; Langel U; Gräslund A; Bedecs K
    FASEB J; 2008 Jul; 22(7):2177-84. PubMed ID: 18296502
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prion inhibition with multivalent PrPSc binding compounds.
    Mays CE; Joy S; Li L; Yu L; Genovesi S; West FG; Westaway D
    Biomaterials; 2012 Oct; 33(28):6808-22. PubMed ID: 22748770
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Monoclonal antibodies inhibit prion replication and delay the development of prion disease.
    White AR; Enever P; Tayebi M; Mushens R; Linehan J; Brandner S; Anstee D; Collinge J; Hawke S
    Nature; 2003 Mar; 422(6927):80-3. PubMed ID: 12621436
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Scrapie prion protein accumulation by scrapie-infected neuroblastoma cells abrogated by exposure to a prion protein antibody.
    Enari M; Flechsig E; Weissmann C
    Proc Natl Acad Sci U S A; 2001 Jul; 98(16):9295-9. PubMed ID: 11470893
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Charged bipolar suramin derivatives induce aggregation of the prion protein at the cell surface and inhibit PrPSc replication.
    Nunziante M; Kehler C; Maas E; Kassack MU; Groschup M; Schätzl HM
    J Cell Sci; 2005 Nov; 118(Pt 21):4959-73. PubMed ID: 16219680
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The tyrosine kinase inhibitor STI571 induces cellular clearance of PrPSc in prion-infected cells.
    Ertmer A; Gilch S; Yun SW; Flechsig E; Klebl B; Stein-Gerlach M; Klein MA; Schätzl HM
    J Biol Chem; 2004 Oct; 279(40):41918-27. PubMed ID: 15247213
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Acridin-9-yl exchange: a proposal for the action of some 9-aminoacridine drugs.
    Sebestík J; Safarík M; Stibor I; Hlavácek J
    Biopolymers; 2006; 84(6):605-14. PubMed ID: 16933221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of novel acridine derivatives in the inhibition of hPrP90-231 prion protein fragment toxicity.
    Villa V; Tonelli M; Thellung S; Corsaro A; Tasso B; Novelli F; Canu C; Pino A; Chiovitti K; Paludi D; Russo C; Sparatore A; Aceto A; Boido V; Sparatore F; Florio T
    Neurotox Res; 2011 May; 19(4):556-74. PubMed ID: 20405353
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Mimicking dominant negative inhibition of prion replication through structure-based drug design.
    Perrier V; Wallace AC; Kaneko K; Safar J; Prusiner SB; Cohen FE
    Proc Natl Acad Sci U S A; 2000 May; 97(11):6073-8. PubMed ID: 10823951
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.